HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

CNXU

Conexeu Sciences Inc. (NASDAQ)

Healthcare — Biotechnology

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.

Strong Buy 1.0 / 5 1 analysts
$10.26
$-0.66 (-6.04%)
Target: $20.00 (94.9%)
Sign in to add CNXU to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$274.54M
P/E Ratio (TTM)-
Forward P/E-19.36
EPS (TTM)$-0.34
Dividend Yield-
Profit Margin-
Revenue Growth-
ROE-
Debt/Equity0.05
Recommendation Strong Buy 1.0
Analyst Target$20.00
Analysts1
Indexes NASDAQ

Technical Indicators

RSI (14)39.2
Beta-
SMA 20-
SMA 40-
52-Week High$18.79
52-Week Low$9.60
50-Day Avg$12.77
200-Day Avg$12.77
Avg Volume78.6K
Volume55.9K

Performance Analysis

BULLISH

CNXU shows predominantly bullish signals based on its fundamentals and technicals.

+ Trading near its 52-week low ($9.60), which could present a value opportunity.
~ RSI at 39.2 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
+ Wall Street consensus is "Strong Buy" from 1 analysts.
+ Average analyst target of $20.00 implies 94.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:04 UTC

Back to Screener Export Report